Novo Nordisk A Quick Ratio (NVO) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Novo Nordisk A  (NYSE: NVO)

Novo Nordisk A's Quick Ratio

NVO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2026, Quick Ratio fell to 1.43 below Novo Nordisk A average.

Within Major Pharmaceutical Preparations industry 373 other companies have achieved higher Quick Ratio than Novo Nordisk A in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 1410 to 5855.

Explain Quick Ratio?
How much Cash & cash equivalents NVO´s has?
What are NVO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NVO Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 0
Q1
Y / Y Current Liabilities Change -93.27 % -99.94 % 4.39 % 4.1 % 1700.74 %
Y / Y Cash & cash equivalent Change -33.8 % 92.37 % -40.83 % -61.67 % 437.7 %
Quick Ratio MRQ 1.43 12.96 1.34 0.65 0.15
NVO's Total Ranking # 5855 # 1410 # 1758 # 3185 # 5113
Seq. Current Liabilities Change 3783.45 % -98.44 % -15.55 % -86.87 % -65.15 %
Seq. Cash & cash equivalent Change 327.58 % -84.9 % 73.43 % -40.89 % 1142.48 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 374
Healthcare Sector # 667
Overall Market # 2009


Quick Ratio Statistics
High Average Low
12.96 1.87 0
(Dec 31 2025)   (Dec 31 2024)




Financial Statements
Novo Nordisk A's Current Liabilities $ 2,282 Millions Visit NVO's Balance sheet
Novo Nordisk A's Cash & cash equivalent $ 3,257 Millions Visit NVO's Balance sheet
Source of NVO's Sales Visit NVO's Sales by Geography


Cumulative Novo Nordisk A's Quick Ratio

NVO's Quick Ratio for the trailling 12 Months

NVO Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 0
12 Months
Y / Y Current Liabilities TTM Growth -92.41 % -60.6 % 298.87 % 307.12 % 327.44 %
Y / Y Cash & cash equivalent TTM Growth -44.13 % -21.74 % -32.03 % 9.65 % 97.45 %
Quick Ratio TTM 1.13 0.32 0.1 0.12 0.15
Total Ranking TTM # 5855 # 1410 # 1758 # 3185 # 5113
Seq. Current Liabilities TTM Growth -74.98 % -69.75 % 0.11 % 0.13 % 29.91 %
Seq. Cash & cash equivalent TTM Growth -12.2 % 2.76 % -20.78 % -21.83 % 22.99 %

Quick ratio ranking by company, industry and sector >> Back to NVO Financial Strength Comparisons >> Go to Compare NVO Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Novo Nordisk A's average Cash & cash equivalent, this led to increase in in Novo Nordisk A's Quick Ratio to 1.13, Quick Ratio remained below NVO average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 373 other companies have achieved higher Quick Ratio than Novo Nordisk A. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending fourth quarter 2025 at 4191.

Explain Quick Ratio?
How much Cash & cash equivalents NVO´s has?
What are NVO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 374
Healthcare Sector # 667
Within the Market # 5855


trailing twelve months Quick Ratio Statistics
High Average Low
12.96 1.87 0
(Dec 31 2025)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Maravai Lifesciences Holdings Inc   3.89 $ 165.922  Millions$ 42.622  Millions
Serina Therapeutics Inc   3.87 $ 24.526  Millions$ 6.340  Millions
Aclaris Therapeutics Inc   3.85 $ 105.416  Millions$ 27.370  Millions
Genelux Corporation  3.77 $ 26.209  Millions$ 6.956  Millions
Scynexis Inc   3.73 $ 59.263  Millions$ 15.900  Millions
Gt Biopharma Inc   3.69 $ 8.923  Millions$ 2.416  Millions
Pulmatrix Inc   3.67 $ 3.324  Millions$ 0.905  Millions
Acurx Pharmaceuticals inc   3.66 $ 9.255  Millions$ 2.527  Millions
Longeveron Inc   3.63 $ 15.758  Millions$ 4.345  Millions
Reviva Pharmaceuticals Holdings Inc   3.63 $ 22.190  Millions$ 6.119  Millions
Xilio Therapeutics Inc   3.62 $ 150.333  Millions$ 41.576  Millions
United Therapeutics Corporation  3.59 $ 2,153.700  Millions$ 599.100  Millions
Vistagen Therapeutics Inc   3.55 $ 45.403  Millions$ 12.795  Millions
Hepion Pharmaceuticals Inc   3.54 $ 2.603  Millions$ 0.736  Millions
Enanta Pharmaceuticals Inc  3.53 $ 163.774  Millions$ 46.442  Millions
Rani Therapeutics Holdings Inc   3.50 $ 43.403  Millions$ 12.395  Millions
Aquestive Therapeutics Inc   3.49 $ 110.734  Millions$ 31.753  Millions
Calcimedica Inc   3.48 $ 8.164  Millions$ 2.347  Millions
Inhibitor Therapeutics Inc   3.38 $ 1.291  Millions$ 0.382  Millions
Rhythm Pharmaceuticals Inc   3.32 $ 340.625  Millions$ 102.522  Millions
Tao Synergies Inc   3.30 $ 3.646  Millions$ 1.104  Millions
Arbutus Biopharma Corp  3.14 $ 17.003  Millions$ 5.409  Millions
Bolt Biotherapeutics Inc   3.12 $ 22.892  Millions$ 7.343  Millions
Kyntra Bio Inc   3.10 $ 87.237  Millions$ 28.114  Millions
Compass Pathways Plc  3.07 $ 466.389  Millions$ 151.904  Millions
Aptevo Therapeutics Inc   3.05 $ 14.525  Millions$ 4.760  Millions
Polaryx Therapeutics Inc   3.04 $ 3.080  Millions$ 1.014  Millions
Nanoviricides inc   3.02 $ 3.213  Millions$ 1.065  Millions
Kiniksa Pharmaceuticals International Plc  2.99 $ 468.093  Millions$ 156.611  Millions
Harmony Biosciences Holdings inc   2.95 $ 640.918  Millions$ 217.340  Millions

Date modified: 2026-09-23T16:04:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.